每周一次特立帕肽对比阿仑膦酸钠治疗高骨折风险骨质疏松女性的随机对照试验:JOINT-05主要结果
这项随机、开放标签、盲法终点试验纳入日本75岁及以上原发骨质疏松高骨折风险女性,比较每周一次皮下注射特立帕肽56.5 μg用72周后序贯阿仑膦酸钠48周与单用阿仑膦酸钠120周的疗效。主要终点72周时形态学椎体骨折发生率特立帕肽组显著低于阿仑膦酸钠组(年发生率0.1334 vs 0.1734,率比0.78,95%CI 0.61-0.99,P=0.04)。
要点
- 每周一次特立帕肽56.5 μg用72周较阿仑膦酸钠显著降低形态学椎体骨折发生率。
- 率比0.78(95%CI 0.61-0.99,P=0.04),年发生率0.1334 vs 0.1734。
- 两组不良事件最常见为感染、胃肠道疾病及肌肉骨骼和结缔组织疾病。
核心结论
- 在骨折高风险的原发骨质疏松女性中,每周一次皮下注射特立帕肽72周较阿仑膦酸钠显著降低形态学椎体骨折发生率。
研究设计与样本
- 前瞻性、随机、开放标签、盲法终点的随机对照试验,纳入日本75岁及以上原发骨质疏松且骨折高风险女性。
- 按1:1随机分配至序贯治疗组(每周一次皮下注射特立帕肽56.5 μg用72周,随后阿仑膦酸钠48周)或阿仑膦酸钠单药治疗120周。
- 共入组1011例(特立帕肽组505例,阿仑膦酸钠组506例),主要分析纳入778例(分别为351例和427例)。
主要发现
- 主要终点72周时形态学椎体骨折发生率特立帕肽组为56例/419.9人年(年发生率0.1334),阿仑膦酸钠组为96例/553.6人年(年发生率0.1734)。
- 率比0.78(95%置信区间0.61至0.99,P=0.04),特立帕肽组显著低于阿仑膦酸钠组。
- 两组不良事件最常见报告的系统器官分类为感染和侵染、胃肠道疾病、肌肉骨骼和结缔组织疾病。
临床怎么用
- 对于75岁及以上原发骨质疏松且骨折高风险女性,可考虑每周一次特立帕肽56.5 μg治疗72周以降低形态学椎体骨折风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: In this randomized, controlled trial, treatment with once-weekly subcutaneous injection of teriparatide for 72 weeks was found to be associated with a significant reduction in the incidence of morphometric vertebral fractures compared with alendronate in women with primary osteoporosis who were at high risk of fracture. INTRODUCTION: To determine whether the anti-fracture efficacy of teriparatide is superior to that of alendronate, a prospective, randomized, open-label, blinded-endpoint trial was performed. METHODS: Japanese women aged at least 75 years were eligible for the study if they had primary osteoporosis and were at high risk of fracture. Patients were randomly assigned in a 1:1 ratio to receive sequential therapy (once-weekly subcutaneous injection of teriparatide 56.5 μg for 72 weeks followed by alendronate for 48 weeks) or monotherapy with alendronate for 120 weeks. The primary endpoint was the incidence of morphometric vertebral fractures at 72 weeks (at the end of teriparatide treatment). RESULTS: Between October 2014 and December 2017, 1011 patients (505 in the teriparatide group and 506 in the alendronate group) were enrolled. Of these, 778 patients (351 and 427, respectively) were included in the primary analysis. The incidence of morphometric vertebral fractures was significantly lower in the teriparatide group (56 per 419.9 person-years, annual incidence rate 0.1334) than in the alendronate group (96 per 553.6 person-years, annual incidence rate 0.1734), with a rate ratio of 0.78 (95% confidence interval 0.61 to 0.99, P = 0.04). In both groups, adverse events were most frequently reported in the following system organ classes: infections and infestations, gastrointestinal disorders, and musculoskeletal and connective tissue disorders. CONCLUSION: Once-weekly subcutaneous injection of teriparatide significantly reduced the incidence of morphometric vertebral fractures compared with alendronate in women with primary osteoporosis who were at high risk of fracture. TRIAL REGISTRATION: jRCTs031180235 and UMIN000015573, March 12, 2019.
引用
- Hagino H, Sugimoto T, Tanaka S, et al. A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05. Osteoporos Int. 2021. PMID: 34002252. doi:10.1007/s00198-021-05996-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。